COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Innovative Molecular Analysis Technologies Program Funding Opportunities

The NCI is very pleased to announce that the Innovative Molecular Analysis Technologies (IMAT) program funding opportunity announcements have been posted for calendar year (CY) 2013. Please visit this website for more information on these announcements. For your convenience, a link to each solicitation is provided below with associated submission deadlines for new applications and resubmissions. Please contact the NCI IMAT program director, Dr. Tony Dickherber (dickherberaj@mail.nih.gov) should you have any questions or concerns.

  • Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21)
    (RFA-CA-13-001)
    National Cancer Institute
    Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013
  • Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33)
    (RFA-CA-13-002)
    National Cancer Institute
    Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013
  • Early-Stage Development of Innovative Technologies for Biospecimen Science (R21)
    (RFA-CA-13-003)
    National Cancer Institute
    Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013
  • Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33)
    (RFA-CA-13-004)
    National Cancer Institute
    Application Receipt Date(s): February 20, 2013; May 20, 2013; September 20, 2013